Biotech Stock Still 700%: What Investors Should Do Today
A biotech stock still 700% has defied gravity, even as it slumps 30% this year. Learn how to read the signals, what a...
It's never too early to start thinking about retirement. Learn when and how to begin planning for a secure financial future.
13,501 articlesA biotech stock still 700% has defied gravity, even as it slumps 30% this year. Learn how to read the signals, what a...
The S&P 500 has slipped this year, yet three tech-focused ETFs powering AI names have kept a higher trajectory over t...
Three growth-focused ETFs have fallen this month as rates move and leadership shifts unsettle risk assets. One fund s...
In a landscape defined by budget cycles and rapid tech shifts, L3Harris Technologies stands out with a 7.1 rating in ...
Coinbase stock stalls $200 after a 14% surge, with traders watching volume and regulatory headlines for the next move...
Geopolitics are shaping energy markets in real time. A fresh disruption from Iran adds a new layer of risk and opport...
Two well-positioned tech companies could be the catalysts for a multi-year fortune-building journey. This guide break...
When the market's fear gauge just spiked, investors wonder what comes next for AI stocks. This guide breaks down the ...
Palantir is venturing into a new market via Polymarket, sparking questions about its AI growth path. This guide lays ...
Peloton has swung from hype to hardship, but its AI-driven pivot could reshape its fortunes. This guide explains what...
JPMorgan has begun a pilot that compares junior bankers' self-reported hours to computer activity, including keystrok...
Moldova's parliament approved a 60-day energy emergency following Russian strikes on Ukraine's grid that cut the Isac...